News Conference News AHA 2025 Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI Todd Neale November 09, 2025
News Conference News AHA 2025 One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients Todd Neale November 08, 2025
News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Conference News AHA 2023 DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI Shelley Wood November 11, 2023
News Conference News AHA 2022 Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5 Yael L. Maxwell November 11, 2022
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2019 Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE Yael L. Maxwell November 21, 2019
News Conference News AHA 2018 REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides Todd Neale November 10, 2018
News Conference News AHA 2017 RE-DUAL PCI Findings Consistent Across Key Subgroups Todd Neale November 16, 2017
News Conference News AHA 2017 GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS Yael L. Maxwell November 14, 2017
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
News Conference News AHA 2015 Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding Todd Neale November 10, 2015